Molecular determinants of the factor VIII/von Willebrand factor complex revealed by BIVV001 cryo-electron microscopy.Fuller, J.R., Knockenhauer, K.E., Leksa, N.C., Peters, R.T., Batchelor, J.
- PubMed: 33569592
- DOI: 10.1182/blood.2020009197
- Primary Citation of Related Structures:
- PubMed Abstract:
- New tool: phenix.real_space_refine
Afonine, P.V., Headd, J.J., Terwilliger, T.C., Adams, P.D.
(2013) Comput Cryst Newsl 4: 43
- Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix.
Liebschner, D., Afonine, P.V., Baker, M.L., Bunkoczi, G., Chen, V.B., Croll, T.I., Hintze, B., Hung, L.W., Jain, S., McCoy, A.J., Moriarty, N.W., Oeffner, R.D., Poon, B.K., Prisant, M.G., Read, R.J., Richardson, J.S., Richardson, D.C., Sammito, M.D., Sobolev, O.V., Stockwell, D.H., Terwilliger, T.C., Urzhumtsev, A.G., Videau, L.L., Williams, C.J., Adams, P.D.
(2019) Acta Crystallogr D Struct Biol 75: 861
- ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps.
(2018) Acta Crystallogr D Struct Biol 74: 519
- Automated structure refinement of macromolecular assemblies from cryo-EM maps using Rosetta.
Wang, R.Y., Song, Y., Barad, B.A., Cheng, Y., Fraser, J.S., DiMaio, F.
(2016) Elife 5: --
Interaction of factor VIII (FVIII) with von Willebrand factor (VWF) is mediated by the VWF D'D3 domains and thrombin-mediated release is essential for hemostasis after vascular injury. VWF-D'D3 mutations resulting in loss of FVIII binding are the underlying cause of von Willebrand Disease (VWD) type 2N ...
Interaction of factor VIII (FVIII) with von Willebrand factor (VWF) is mediated by the VWF D'D3 domains and thrombin-mediated release is essential for hemostasis after vascular injury. VWF-D'D3 mutations resulting in loss of FVIII binding are the underlying cause of von Willebrand Disease (VWD) type 2N. Furthermore, the FVIII-VWF interaction has significant implications for the development of therapeutics for bleeding disorders, particularly hemophilia A, where endogenous VWF clearance imposes a half-life ceiling on replacement FVIII therapy. To understand the structural basis of FVIII engagement by VWF, we solved the structure of BIVV001 by cryo-electron microscopy to 2.9 Å resolution. BIVV001 is a bioengineered clinical-stage FVIII molecule for the treatment of hemophilia A. In BIVV001, VWF-D'D3 is covalently linked to an Fc domain of a B domain-deleted recombinant FVIII (rFVIII) Fc fusion protein, resulting in a stabilized rFVIII/VWF-D'D3 complex. Our rFVIII/VWF structure resolves BIVV001 architecture and provides a detailed spatial understanding of previous biochemical and clinical observations related to FVIII-VWF engagement. Notably, the FVIII acidic a3 peptide region (FVIII-a3), established as a critical determinant of FVIII/VWF complex formation, inserts into a basic groove formed at the VWF-D'/rFVIII interface. Our structure shows direct interaction of sulfated Y1680 in FVIII-a3 and VWF-R816, which, when mutated, leads to severe hemophilia A or VWD type 2N, respectively. These results provide insight on this key coagulation complex, explain the structural basis of many hemophilia A and VWD type 2N mutations, and inform studies to further elucidate how VWF dissociates rapidly from FVIII upon activation.
SANOFI, Waltham, Massachusetts, United States.